$HNGE

Mecklenburg Gabriel M.I. sold $14.0M of HNGE

Mecklenburg Gabriel M.I. sold 150,000 shares of Hinge Health, Inc. (HNGE) at an average of $93.22 ($88.98–$94.70, $13.98M total) across 6 trades on 2026-09-14 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Mecklenburg Gabriel M.I.
Published Sep 15, 2026, 11:21 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 15, 2026, 11:23 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$HNGE
Bearish
high confidence
Mentioned
$HNGE
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$HNGEBearishMed
01

Why it matters

The disclosure provides fresh material for traders to reassess Hinge Health's valuation and insider sentiment.

02

Market read

Direct insider sell of $14M may trigger short-term price decline; traders should monitor price action.

03

What to watch

Potential tax planning or diversification motives; the 10b5-1 plan may have been pre-set.

Relevance 6/10Novelty 8/10Timing: post-market 2026-09-14

Background

Form 4 filing discloses insider transactions; director sells all holdings via a pre-arranged plan.

Company-level read

Ticker impact

$HNGEBearishHigh confidence
Context

Director Mecklenburg Gabriel M.I. sold all 150,000 shares for $13.98M via a 10b5-1 plan, leaving zero holdings.

Expected impact

Short-term downward pressure expected; traders may consider short positions or reduce exposure.

Evidence & confidence

The sale represents a large $14M disposition by an insider with no remaining stake, indicating possible negative outlook.

Market effects

May raise concerns for the digital health sector about insider confidence.

Limited to US markets where HNGE trades.

Low global impact; primarily affects Hinge Health investors.

Counterpoint

The sale could be a routine liquidity event unrelated to company fundamentals.

Key entities

  • Hinge Health, Inc.

    Digital health company providing musculoskeletal care platforms.

  • Mecklenburg Gabriel M.I.

    Director of Hinge Health who executed the sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$HNGEHighAI 8/10

Could Hinge Health (HNGE) Stock Win as Digital Healthcare Expands Beyond MSK Care?

Hinge Health (NYSE:HNGE) raised its 2026 revenue guidance to $856M-$860M, up from $822.16M consensus. Q2 2026 revenue grew 53% YoY to $213M, with non-GAAP operating income doubling to $62M. The company announced a $105M acquisition of Cylinder Health and expanded its share repurchase program by $300M. Analysts RBC and Truist raised price targets to $110 and $112, respectively, citing strong growth and platform expansion.

$HNGEMedAI 8/10

HNGE Stock Surges Nearly 90% YTD: Can Its Growth Story Continue?

Hinge Health (HNGE) stock has risen 90% YTD, outperforming industry and S&P 500. Q2 revenue grew 53% YoY to $213M, with 2026 guidance raised to $856-$860M. AI and automation improved margins, while new care programs expand market reach. Analysts project 2026 EPS of $2.50 and 2027 EPS of $3.29. Growth is driven by member yield, AI efficiency, and new care offerings, but execution risks remain.

$HNGEMed

Jim Cramer says one stock hitting new highs is still a screaming buy

Jim Cramer reiterated a triple buy call on Hinge Health (HNGE) on “Mad Money” Aug. 11. The stock hit a new all-time high of $93.13 on Aug. 10 and is up about 85.83% YTD, per Yahoo Finance. Hinge reported Q2 2026 revenue of $213 million (+53% YoY), free cash flow of $99.6 million, and raised FY guidance to $856-$860 million. It also agreed to a $105 million cash acquisition (Cylinder Health) to expand into GI care.

$HNGEMed

Hinge Health (HNGE) Just Bought Its Way Into A New Market, So Now What?

Hinge Health (NASDAQ:HNGE) reported Q2 revenue of $213 million, up 53% year over year, above guidance of $200 million to $202 million. Gross margin rose to 87% and operating income to $62 million. The company said it used $105 million cash to acquire Cylinder Health for gastrointestinal care, while also expanding its migraine offering. It raised FY revenue guidance to $856 million to $860 million and authorized a $300 million buyback.

$HNGEHighAI 9/10

Why is Hinge Health stock surging today?

Hinge Health (HNGE) shares rose 11.6% after the company reported Q2 2026 revenue of $212.8M (+53% YoY) and non-GAAP diluted EPS of $0.59 vs $0.13 consensus. Free cash flow exceeded $100M. Hinge raised FY2026 revenue guidance to $818M-$824M and Q3 guidance to $223M-$225M, and agreed to buy Cylinder Health for $105M cash. Analysts lifted price targets.